Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/MED.0000000000000256 http://scihub22266oqcxt.onion/10.1097/MED.0000000000000256 C4898193!4898193!27032061     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Opin+Endocrinol+Diabetes+Obes 2016 ; 23 (3): 225-32 Nephropedia Template TP {{tp|p=27032061|t=2016. Novel Treatment Strategies in Congenital Adrenal Hyperplasia |pdf=|usr=}}{{27032061}} gab.com Text Novel Treatment Strategies in Congenital Adrenal Hyperplasia JO: Curr Opin Endocrinol Diabetes Obes http://www.kidney.de/pget.php?&tw=1&pmid=27032061 #FOAvip Purpose of review: In recent years, important steps have been taken to improve the treatment of congenital adrenal hyperplasia (CAH), a relatively stagnant area for decades. In this review, we summarize these advances and propose future lines of investigation. Recent findings: The two main goals of CAH treatment are to replace the deficient hormones when necessary and to dampen the adrenorcorticotropin (ACTH) activation and the ensuing adrenal androgen excess. Glucocorticoids have been the mainstay of CAH treatment, but available preparations only partially meet the clinical needs. Recent efforts have focused on improving the delivery of glucocorticoid replacement agents, to closer mimic the physiologic secretion pattern. Examples include modified-release oral glucocorticoids and continuous subcutaneous hydrocortisone pumps. Furthermore, non-glucocorticoid approaches to address the androgen excess have emerged, such as inhibition of key androgenic enzymes and ACTH secretion blockade by corticotropin-releasing hormone-receptor antagonists. Summary: The promising recent progress made in CAH treatment brings new perspectives for individualized care in this complex disease. Twit Text FOAVip Novel Treatment Strategies in Congenital Adrenal Hyperplasia ????Curr Opin Endocrinol Diabetes Obes http://www.kidney.de/pget.php?&tw=1&pmid=27032061 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27032061 #FOAvip English Wikipedia <ref>{{Cite pmid|27032061}}</ref> Novel Treatment Strategies in Congenital Adrenal Hyperplasia #MMPMID27032061 Turcu AF; Auchus RJ Curr Opin Endocrinol Diabetes Obes 2016[Jun]; 23 (3): 225-32 PMID27032061show ga Purpose of review: In recent years, important steps have been taken to improve the treatment of congenital adrenal hyperplasia (CAH), a relatively stagnant area for decades. In this review, we summarize these advances and propose future lines of investigation. Recent findings: The two main goals of CAH treatment are to replace the deficient hormones when necessary and to dampen the adrenorcorticotropin (ACTH) activation and the ensuing adrenal androgen excess. Glucocorticoids have been the mainstay of CAH treatment, but available preparations only partially meet the clinical needs. Recent efforts have focused on improving the delivery of glucocorticoid replacement agents, to closer mimic the physiologic secretion pattern. Examples include modified-release oral glucocorticoids and continuous subcutaneous hydrocortisone pumps. Furthermore, non-glucocorticoid approaches to address the androgen excess have emerged, such as inhibition of key androgenic enzymes and ACTH secretion blockade by corticotropin-releasing hormone-receptor antagonists. Summary: The promising recent progress made in CAH treatment brings new perspectives for individualized care in this complex disease. äNovel Treatment Strategies in Congenital Adrenal Hyperplasia (epmc).pdf DeepDyve Pubget Overpricing